Cheapest Semaglutide Provider: A Clinical Look at What the Big Telehealth Brands Actually Charge

Patients researching semaglutide or tirzepatide almost always encounter the same four national platforms first: Hims & Hers, Ro, Henry Meds, and LifeMD. Their marketing is polished and their advertised prices look competitive. But the number in the ad rarely reflects what you’ll actually pay month over month — and that distinction matters clinically as much as financially, since cost is one of the leading reasons patients discontinue GLP-1 therapy prematurely.

Why the Advertised Price Isn’t the Real Price

All four of these platforms operate on the same underlying model: a recurring membership or consultation fee, billed separately from the medication itself.

Hims & Hers. A $39 first-month membership renewing at $149/month, with medication priced as a separate line item on top.

LifeMD. A consultation/membership fee, commonly reported between $30–$100, added to medication cost. Total monthly spend has been documented ranging from roughly $150 to over $700, depending on medication and plan tier.

Henry Meds and Ro. Both advertise a low entry price, but independent trackers that monitor these platforms consistently report the real ongoing cost lands higher once dosing tier and continued access are factored in. The exact figures vary meaningfully by source, which is itself informative.

We’re intentionally not printing a single definitive dollar figure for any of these companies. Pricing in the compounded GLP-1 space is genuinely volatile right now: weekly-tracked pricing indexes show real month-to-month movement, and in early 2026 the FDA issued warning letters to more than 30 companies offering compounded GLP-1 medications — a regulatory shift that continues to affect pricing and availability across the market. Any specific figure we published today could be inaccurate within weeks. What’s more stable, and more clinically relevant, is the pricing structure itself.

A subscription-based structure means the patient pays an access fee every month, independent of whether the dose changes or whether a check-in occurs that month, for as long as the subscription remains active. Discontinuing the platform frequently means losing not just medication access, but records and treatment history as well.

Our Model: Pay-Per-Vial, No Membership

TRT Miami prices semaglutide and tirzepatide by the vial, not by subscription. Patients pay for a real, multi-week medication supply sourced from a licensed U.S. compounding pharmacy — nothing else is billed. There is no recurring membership fee layered on top of the prescription, and no penalty for pausing treatment.

Because vials are priced and sold upfront rather than billed on a recurring monthly cycle, the patient’s true monthly cost is a direct function of their actual prescribed dose — not a flat rate calculated around an average subscriber. For patients starting at lower doses in particular, this structure frequently results in meaningfully lower total cost than the major telehealth platforms, without any reduction in clinical oversight.

Questions Worth Asking Any Provider

Before selecting a GLP-1 provider — including us — we’d recommend confirming the following, rather than relying on the advertised starting price alone:

• Is there a membership or subscription fee charged in addition to medication cost?
• Does pricing change after an introductory period, and is that disclosed upfront?
• What pharmacy compounds the medication, and is it licensed and accredited?
• What happens to your provider relationship and records if you discontinue?

The Bottom Line

Cost transparency is a clinical issue as much as a financial one — patients who understand their true ongoing cost before starting therapy are better positioned to stay on treatment long enough to see results. We built our pricing model around that principle. Whichever provider you choose, we’d encourage asking the questions above before committing.

Sources: FDA warning letters to compounded GLP-1 companies, reported by Telehealth Ally, April 2026. Pricing structures verified against GLP Chart’s weekly-tracked pricing index and independent provider reviews, as of August 2026.

This article is for general informational purposes and isn’t a substitute for personalized medical advice. Pricing for any provider mentioned, including our own, is subject to change — please confirm current pricing directly before enrolling with any provider.